Business
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 20241 IBSRELA expected to achieve $410-430 million in revenue in 2026 IBSRELA revenue expected to reach $1 billion in 2029 WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, f
About this update from Ardelyx, Inc.
[{"type":"image","alt":"Ardelyx, Inc.","displaySize":"","headline":null,"caption":"Ardelyx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":69,"url":"https://media.zenfs.com/en/globenewswire.com/0b16c7d3f50416d895ec92e34e19858e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MgPvxPnNoevfPj4GVpeYhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0b16c7d3f50416d895ec92e34e19858e","width":300,"height":69}},"lazy":false},{"type":"text","content":"Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 ","length":115,"tagName":"p"},{"type":"text","content":"IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 20241","length":83,"tagName":"p"},{"type":"text","content":"IBSRELA expected to achieve $410-430 million in revenue in 2026","length":63,"tagName":"p"},{"type":"text","content":"IBSRELA revenue expected to reach $1 billion in 2029","length":52,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today provided its preliminary and unaudited fourth quarter and full year 2025 product revenue, currently expected product revenue for 2026 and updated long-term outlook for IBSRELA, along with recent business updates.","length":473,"tagName":"p"},{"type":"text","content":"“For Ardelyx, 2025 was a remarkable year characterized by outstanding commercial execution and performance. IBSRELA delivered significant revenue growth of 73% over 2024, and we successfully protected patient access to XPHOZAH. We advanced our pipeline by commencing a Phase 3 program for IBSRELA in chronic idiopathic constipation and began development of a next generation NHE3 inhibitor with RDX10531, creating momentum behind our efforts to continue positioning Ardelyx for durable long-term growth,” said Mike Raab, president and chief executive officer. “We enter 2026 exceptionally well positioned to deliver significant growth and long-term value creation as we invest in our business to accelerate our commercial opportunities. We have first-in-class medicines in areas of unm...